Zeo Scientifix, INC

Zeo ScientifiX announces the launch of ZEO Xperience, a three-day educational event for healthcare professionals focused on regenerative biologics.

ZEO ScientifiX announces strategic initiatives to enhance regenerative medicine research, physician education, and scientific collaboration within Florida's growing life sciences sector.

Zeo ScientifiX announced significant year-over-year revenue growth of 124.6% for the quarter and 79.9% for the six months ended April 30, 2026, driven by its regenerative biologics portfolio.

Zeo ScientifiX will host a virtual educational webinar for healthcare professionals on July 22, 2026, focusing on the advancements and regulatory landscape of regenerative medicine in the Southeast.

Zeo ScientifiX announced its Medical Advisory Board member, Dr. Constantino Mendieta, utilized donated products during a humanitarian mission in Peru to treat child burn victims.

Zeo ScientifiX, Inc. has granted a total of 3,890,000 stock options to key executives, consultants, and directors under its 2021 Incentive Stock Plan.

Zeo ScientifiX, Inc. announced a significant increase in revenue for the second quarter of fiscal year 2026, driven by strong performance in its allogenic biologic products.

Zeo ScientifiX reported a 32.7% revenue increase and reduced net loss, but continues to face substantial doubt about its ability to continue as a going concern amidst regulatory and legal challenges.

Zeo ScientifiX reported a significantly wider net loss and expressed substantial doubt about its ability to continue as a going concern, despite revenue growth from its PPX service platform.

Zeo ScientifiX, a clinical-stage biopharmaceutical company, reported an increased net loss for the six months ended April 30, 2025, alongside a significant going concern warning and shifts in product revenue streams.

Zeo ScientifiX's Q1 2025 revenue decreased slightly due to lower biologic product sales, offset by growth in its PPX service platform.

Zeo ScientifiX reported a net loss of $1.012 million for the third quarter of 2024, with a decrease in revenue and ongoing concerns about its ability to continue as a going concern.

Zeo ScientifiX reports increased revenues driven by its PPX platform and strategic partnerships, yet faces significant net losses and going concern doubts for fiscal year 2025.

Zeo ScientifiX announces its fiscal year 2024 results, navigating regulatory challenges and focusing on clinical trials and international expansion.

Organicell Regenerative Medicine, Inc. reports a decrease in revenue for fiscal year 2023, while managing operating expenses and navigating a complex regulatory environment.

Wendy Grey and Greyt Ventures, LLC were granted a total of 1.25 million stock options in Zeo ScientifiX, Inc. on June 10, 2026.

CEO and CFO Ian Bothwell was granted 1.25 million stock options in Zeo ScientifiX, Inc. under the 2021 Equity Incentive Plan.

Chief Medical Officer George Craig Shapiro was granted 1.25 million stock options in Zeo ScientifiX, Inc.

Director Charles Luther Bretz was granted 80,000 stock options in Zeo ScientifiX, Inc. as part of the company's 2021 Equity Incentive Plan.

Zeo ScientifiX, Inc. director and 10% owner Wendy Grey was granted 175,000 restricted common shares under the company's 2021 Equity Incentive Plan.

Zeo ScientifiX, Inc.'s CEO and CFO, Ian T. Bothwell, was granted 175,000 restricted common shares under the company's 2021 Equity Incentive Plan.

Zeo ScientifiX has filed an amendment to its S-1 registration statement, covering the proposed resale of up to 4,426,823 shares of its common stock by selling stockholders.

Zeo ScientifiX is registering 3,826,823 shares of common stock for resale by selling stockholders, with the company not receiving any proceeds from the sale itself.

Wendy Grey and Greyt Ventures, LLC have amended their Schedule 13D filing, increasing their beneficial ownership and voting power in Zeo Scientifix, Inc. to 49.38%.

Ian Bothwell, CEO of Zeo Scientifix, has increased his beneficial ownership to 46.1% of the company's voting power through stock options and preferred stock.

Ian Bothwell, CEO and CFO of Zeo Scientifix, Inc., has increased his beneficial ownership and voting power to 40.2% through stock options and restricted shares.

Wendy Grey and Greyt Ventures, LLC increased their beneficial ownership in Zeo Scientifix, Inc., now holding 43.02% of the total voting power through common and preferred stock.

Skycrest Holdings, LLC has increased its beneficial ownership in Zeo Scientifix, Inc. to 7.04% through recent open market purchases.

Skycrest Holdings, LLC has filed an Amendment No. 3 to its Schedule 13D, reporting an increased beneficial ownership of 6.22% in Zeo Scientifix, Inc. through open market purchases.

George Shapiro, M.D. has filed an amended Schedule 13G, reporting beneficial ownership of 1,311,271 shares, representing 15.1% of Zeo Scientifix, Inc.'s common stock.